For the development of more personalized medicine for ICI refractory oral cancer patients, further studies are necessary to elucidate the synergistic effects of CD36 inhibitors in combination with ICIs and to evaluate the utility of CD36 expression as a predictive biomarker for the response to immunotherapy. The gene discussed is CD36; the disease is lip and oral cavity carcinoma.